- Home
- EVLV vs ETNB Comparison
EVLV vs ETNB Comparison
Compare EVLV & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVLV
- ETNB
- Stock Information
- Founded
- EVLV 2013
- ETNB 2018
- Country
- EVLV United States
- ETNB United States
- Employees
- EVLV N/A
- ETNB N/A
- Industry
- EVLV Computer peripheral equipment
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EVLV Technology
- ETNB Health Care
- Exchange
- EVLV Nasdaq
- ETNB Nasdaq
- Market Cap
- EVLV 1.4B
- ETNB 1.5B
- IPO Year
- EVLV N/A
- ETNB 2019
- Fundamental
- Price
- EVLV $7.46
- ETNB $14.85
- Analyst Decision
- EVLV Strong Buy
- ETNB Buy
- Analyst Count
- EVLV 4
- ETNB 10
- Target Price
- EVLV $8.88
- ETNB $22.31
- AVG Volume (30 Days)
- EVLV 4.3M
- ETNB 9.4M
- Earning Date
- EVLV 08-14-2025
- ETNB 11-06-2025
- Dividend Yield
- EVLV N/A
- ETNB N/A
- EPS Growth
- EVLV N/A
- ETNB N/A
- EPS
- EVLV N/A
- ETNB N/A
- Revenue
- EVLV $121,011,000.00
- ETNB N/A
- Revenue This Year
- EVLV $31.07
- ETNB N/A
- Revenue Next Year
- EVLV $17.67
- ETNB N/A
- P/E Ratio
- EVLV N/A
- ETNB N/A
- Revenue Growth
- EVLV 36.64
- ETNB N/A
- 52 Week Low
- EVLV $2.04
- ETNB $4.16
- 52 Week High
- EVLV $8.91
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- EVLV 41.95
- ETNB 80.12
- Support Level
- EVLV $7.63
- ETNB $14.67
- Resistance Level
- EVLV $8.02
- ETNB $14.93
- Average True Range (ATR)
- EVLV 0.40
- ETNB 0.13
- MACD
- EVLV -0.13
- ETNB 0.19
- Stochastic Oscillator
- EVLV 10.71
- ETNB 97.08
About EVLV Evolv Technologies Holdings Inc.
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).